A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Inclusion Criteria

• •Participant must be ≥ 18 years of age.
• •Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
• •Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
• •Parts 2A, 1D, 2D: ccRCC.
• •i) Part 1B: solid tumors with KRAS G12C mutation.
• •ii) Part 2B: NSCLC with KRAS G12C mutation.
• •iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
• •Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
• •Participants must have measurable disease per RECIST v1.1.